Security Snapshot

CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) Institutional Ownership

CUSIP: 23255M105

13F Institutional Holders and Ownership History from Q1 2019 to Q4 2023

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / COMMON STOCK
Symbol
CYCN on Nasdaq
Shares outstanding
4,330,313
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK is tracked under CUSIP 23255M105.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2023 and Q4 2023.
  • Reported value moved from $2,000 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 23255M105?
CUSIP 23255M105 identifies CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Significant Owners of CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% 649,547 FMR LLC 30 Apr 2026

Institutional Holders of CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2023 Q4 0 $0 -$2,000 0
2023 Q3 552 $2,000 $3.62 1
2023 Q2 552 $2,000 -$17,810,737 $3.62 1
2023 Q1 20,630,088 $8,949,493 +$16,936 $0.43 30
2022 Q4 20,827,653 $13,665,576 -$347,030 $0.66 36
2022 Q3 21,236,761 $18,262,273 +$225,673 $0.86 29
2022 Q2 20,901,901 $11,469,174 -$2,261,052 $0.55 32
2022 Q1 23,051,679 $25,583,454 -$790,969 $1.11 42
2021 Q4 23,664,601 $40,699,713 -$4,573,203 $1.72 48
2021 Q3 24,690,641 $75,797,940 +$263,245 $3.07 52
2021 Q2 24,615,826 $96,000,462 +$9,555,790 $3.90 60
2021 Q1 22,395,892 $62,484,018 +$1,379,472 $2.79 67
2020 Q4 21,864,958 $66,903,716 -$6,229,664 $3.06 69
2020 Q3 22,941,416 $139,523,457 +$32,049,269 $6.08 65
2020 Q2 17,688,979 $104,540,887 -$4,008,711 $5.91 67
2020 Q1 18,528,720 $49,097,876 +$8,211,551 $2.65 67
2019 Q4 15,376,074 $41,819,093 -$70,347,297 $2.72 68
2019 Q3 19,547,298 $236,934,655 +$1,931,372 $12.12 84
2019 Q2 19,469,585 $222,922,553 +$213,114,445 $11.45 93
2019 Q1 855,056 $12,666,000 +$12,665,000 $15.13 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .